07:00 , May 18, 2015 |  BioCentury  |  Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc .'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); X-linked inhibitor of apoptosis (XIAP)

Cancer INDICATION: Cancer In vitro and mouse studies identified a macrocylic antagonist of cIAP1 and XIAP that could help treat cancer. In vitro screening of a cyclic peptidomimetic library identified a lead compound that inhibited...
07:00 , Aug 21, 2014 |  BC Innovations  |  Tools & Techniques

Circling back to basics

Macrocycles have been a hot topic for chemists and pharmacologists alike for the promise they hold of reaching druggable targets that small molecules cannot. Although they are still much more challenging than small molecules to...
07:00 , Aug 18, 2014 |  BioCentury  |  Finance

Flagship's fashion

Venture investment models come and go out of fashion, but Flagship Ventures has stuck with its thesis that novel, early stage platform companies with significant disruptive potential are the way to go. And rather than...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Deciphera management update

Deciphera Pharmaceuticals LLC , Lawrence, Kan.   Business: Cancer   Hired: Michael Taylor as president, CEO and a director, formerly CEO of Ensemble Therapeutics Corp. ; he succeeds Daniel Flynn, who becomes CSO and remains...
08:00 , Feb 24, 2014 |  BioCentury  |  Tools & Techniques

Bigger is better

X-Chem Inc. has developed a screening platform and library of DNA-encoded small molecules that enable the identification of high-quality lead candidates against difficult targets. So far, the platform has yielded a handful of discovery deals,...
07:00 , Aug 15, 2013 |  BC Innovations  |  Targets & Mechanisms

IL-17 inhibitors: good news, bad news

New partnerships and release of Phase III data highlight a flurry of activity this summer around the autoimmune target IL-17A . Now, emerging research suggests companies developing inhibitors of IL-17A signaling have both a repurposing...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Ensemble Therapeutics, Novartis deal

Ensemble granted Novartis exclusive, worldwide rights to its lead program of small molecule macrocyclic antagonists of IL-17A identified using Ensemble's Ensemblin technology. The oral compounds are in preclinical testing. Ensemble will work with Novartis on...
00:05 , Aug 7, 2013 |  BC Extra  |  Top Story

Ensemble licenses IL-17 program to Novartis

Ensemble Therapeutics Corp. (Cambridge, Mass.) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to its lead program of small molecule macrocyclic antagonists of IL-17A identified using Ensemble's Ensemblin technology. The oral compounds are in preclinical...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Alexion, Ensemble Therapeutics deal

Ensemble partnered with Alexion to use Ensemble's Ensemblin technology to discover macrocyclic compounds against undisclosed targets selected by Alexion for ultra-rare disorders. Ensemble will receive an undisclosed upfront payment and research support. The biotech also...